COX-1 and COX-2 Expression in Canine Cutaneous, Oral and Ocular Melanocytic Tumours

Pires, Isabel; García, A. Urpegui; Prada, Justina; Queiroga, Felisbina L.

doi:10.1016/j.jcpa.2010.01.016

Cited by 52 publications

(77 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Mohammed et al 28 provided the first report on COX-2 expression in canine melanomas; they observed that COX-2 was expressed by 60% of oral malignant melanoma, but they did not study the relationship between COX-2 expression and other prognostic parameters used to establish melanoma malignancy. Pires et al 31 more recently studied COX-2 in cutaneous, oral, and ocular melanocytic neoplasms. They found COX-2 expression in 11 of 29 cutaneous melanocytic neoplasms (30%; 9 in a high or moderate expression) and 9 of 9 oral melanomas (89%; 8 in a high or moderate expression), with a higher proportion of COX-2 expression in oral neoplasias than its cutaneous counterpart; as such, a relationship between the high expression of COX-2 and the histopathologic grade of malignancy was established.…”

Section: Discussionmentioning

confidence: 99%

Cyclooxygenase-2 Expression Is Related With Localization, Proliferation, and Overall Survival in Canine Melanocytic Neoplasms

et al. 2011

View full text Add to dashboard Cite

A direct relationship has been firmly established between cyclooxygenase-2 (COX-2) expression and malignant behavior in human melanoma. This report examines the relationship between COX-2 expression and tumor location, mitotic and proliferative indices, degree of T CD3 þ lymphocyte infiltration, overall survival, and frequency of recurrence and metastasis of 57 melanocytic tumors (25 oral and 32 cutaneous). COX-2 was highly or moderately expressed in 88% of oral neoplasms (22 of 25), whereas for their cutaneous counterparts, COX-2 expression was low or insignificant in 75% of cases (24 of 32). High and moderate COX-2 expression levels were observed in 73% of melanocytic tumors with a mitotic index ! 3 per 10 high-power fields (26 of 36), whereas in 81% of tumors with a mitotic index < 3 (17 of 21), expression was mild or absent. There were 41 cases with known clinical outcomes; of those showing high, moderate, and mild COX-2 expression, 83.3% (10 of 12), 37.5% (3 of 8), and 25% (2 of 8) died, respectively, whereas 100% of animals showing no COX-2 expression (13 of 13) were still alive at the last follow-up. COX-2 expression was statistically correlated with tumor location, mitotic and percentage Ki-67 proliferative indices, and overall survival, frequency of neoplastic recurrence and metastasis. Regression analysis also showed disease-specific predictive value for COX-2 expression for subjects with melanocytic neoplasms. Additionally, only high COX-2 expression showed significant differences in overall survival, in comparison with moderate, mild, or absent expression. These results suggest that high COX-2 expression may be considered a prognostic biomarker and potentially as a target for therapeutic and preventive strategies in canine melanocytic neoplasms. Keywords cyclooxygenase-2, canine, melanoma, prognosisCanine melanocytic neoplasms occur most frequently in the skin and oral cavity. Classically, body location is one criterion used to establish a prognosis of these tumors. 1,7,10,36 In the skin, melanocytic neoplasms account for 4 to 20% of all cutaneous neoplasms, of which fewer than 5% are malignant. 16,32 Yet canine oral melanomas account for 30 to 40% of all neoplasms in the head and are considered malignant, 36 with poorer prognosis and lower survival rates than their cutaneous melanocytic counterparts. The reasons for this more aggressive behavior are not clear. Recent data suggest that this malignancy may be due to a higher atypia and proliferation rate observed in oral melanomas.27,37 However, several reports suggest a lack of correlation between tumor location and clinical course. 6,20 Of the extensive number of factors used in human pathology to establish an accurate prognosis of melanocytic neoplasms, 40 the mitotic index and Ki-67 proliferation index are the factors that have shown the best correlation with clinical outcome of canine melanocytic neoplasms. 27,[34][35][36][37] Although the mitotic index is considered the most reliable feature for establishing the biological behavior of cu...

show abstract

Section: Discussionmentioning

confidence: 99%

Cyclooxygenase-2 Expression Is Related With Localization, Proliferation, and Overall Survival in Canine Melanocytic Neoplasms

et al. 2011

View full text Add to dashboard Cite

show abstract

“…Estudios en medicina veterinaria han evidenciado aumento en la expresión de COX-2 en diversos tipos tumorales, entre ellos el carcinoma inflamatorio (18,(26)(27)(28). Por este motivo, es preconizado el tratamiento con inhibidores de COX-2 en perras acometidas por este tipo de tumor.…”

Section: Discussionunclassified

Evaluación clínica, epidemiológica y terapéutica en 14 casos de carcinoma inflamatorio mamario canino

Silva¹,

Huppes²,

Nardi³

et al. 2014

Rev. Med. Vet.

View full text Add to dashboard Cite

Con el objetivo de evaluar los aspectos clínicos, edad, raza, presencia de metástasis, protocolo quimioterapéutico, utilización de inhibidores de COX-2 y sobrevida en caninas diagnosticadas con carcinoma inflamatorio, en el Hospital Veterinario de Uberaba (HVU), se realizó un análisis retrospectivo de las historias clínicas de 14 hembras caninas atendidas en el HVU entre julio de 2011 y julio de 2012, con diagnóstico de carcinoma inflamatorio mamario. Las razas acometidas fueron mestizo, poodle, terrier brasilero, teckel y pastor belga. Edad media: 11,1 años. En 7 animales fueron detectados focos de metástasis a distancia. De ellos 5 pacientes recibieron como único tratamiento inhibidores de COX-2 y apenas 4 recibieron tratamiento quimioterapéutico. El protocolo, constituido por piroxicam, ciclofosfamida, carboplatina y doxorrubicina, presentó el mayor tiempo de sobrevida (210 días). En conclusión, el carcinoma inflamatorio es una enfermedad de mal pronóstico, poco tiempo de sobrevida, y ocasiona alteraciones sistémicas que disminuyen la respuesta terapéutica. Aparentemente la modalidad terapéutica más indicada es la asociación de inhibidores de COX-2 y quimioterapéuticos; sin embargo, son necesarios estudios clínicos controlados para evaluar estas sugestiones.

show abstract

“…A expressão da COX-2 vem sendo correlacionada com a progressão de melanomas em seres humanos e foi sugerido que pode ser um método de diferenciar melanomas de lesões melanocíticas benignas e formular um prognóstico (FIGUEIREDO et al, 2003;PIRES et al, 2010). O aumento da expressão da COX-2 está relacionado com o desenvolvimento e progressão de diversas neoplasias epiteliais (GOULET et al, 2003).…”

Section: Ciclooxigenage-2 (Cox-2)unclassified

“…O melanoma canino é uma neoplasia com potencial metastático e é resistente à maioria dos regimes terapêuticos. Para avaliar a eficácia de tratamentos como os AINEs, conhecimento sobre a expressão da COX pelas células tumorais é necessário (PIRES et al, 2010).…”

COX-1 and COX-2 Expression in Canine Cutaneous, Oral and Ocular Melanocytic Tumours

Cited by 52 publications

References 42 publications

Cyclooxygenase-2 Expression Is Related With Localization, Proliferation, and Overall Survival in Canine Melanocytic Neoplasms

Cyclooxygenase-2 Expression Is Related With Localization, Proliferation, and Overall Survival in Canine Melanocytic Neoplasms

Evaluación clínica, epidemiológica y terapéutica en 14 casos de carcinoma inflamatorio mamario canino

<b>Estudo imunoistoquímico das neoplasias melanocíticas uvais em cães</b>

Contact Info

Product

Resources

About